# CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults

> **NIH NIH UL1** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 · $169,963

## Abstract

Abstract/Summary of Parent Award
Since inception in 2008, the UNC CTSA affiliate, the North Carolina Translational and Clinical Sciences Institute
(TraCS) has transformed clinical and translational science at UNC through interdisciplinary research, training,
collaboration with partners and stakeholders, and strong engagement across the CTSA consortium. We have
built a dynamic regional network of universities, research institutes, health care providers, and >130 community
organizations across our state. In the current funding period, we have added NC State University to RTI
International and NC A&T University as full partners in our CTSA hub. In the funding period 2013-2023, our goal
is to translate the best science from UNC and across the CTSA consortium into creative, effective, and accessible
clinical and community interventions, addressing the public health problems of our state and advancing national
CTSA goals. We accomplish through 5 aims: Aim 1. Workforce Development: Develop and support a skilled
and diverse clinical and translational research workforce to advance translational innovations and address
healthcare priorities. Aim 2. Collaboration and Engagement: Engage diverse stakeholders as active partners in
translational research, and promote innovative approaches to team science. Aim 3. Integration: Integrate
translational research across the research continuum, disciplines, populations, and throughout the lifespan. Aim
4. Methods/Processes: Develop and disseminate innovative methods and approaches to address scientific and
operational barriers to translating scientific findings. Aim 5. Informatics: Incorporate cutting-edge informatics
tools and methodologies in every aspect of translational research.
This diversity supplement application by Nadja Vielot, PhD will use real-world Medicare claims data to study
the post-licensure experience in the United States with recombinant herpes zoster vaccine (RZV). The aims of
the proposal are to: 1) Estimate RZV effectiveness against herpes zoster, post-herpetic neuralgia (PHN) and
herpes zoster ophthalmicus (HZO) in adults ages >65, and 2) Estimate the effectiveness of RZV in individuals
with altered immunocompetence. Dr. Vielot will utilize the following CTSA Program resources for the research
and training plan:
Comparative Effectiveness Research: This Service will facilitate the process of securing Medicare data and
oversight of the analyses.
Informatics and Data Science: This Service will be used as part of Aim 3 to obtain data from the Carolina Data
Warehouse for Health (CDW-H) and for assistance in linking CDW-H data to Medicare claims data.
Regulatory Service: Dr. Vielot will use this service for guidance on completing the appropriate IRB and data
use agreements required for the project.
Workforce Development Program: Dr. Vielot will participate in the following WD training opportunities: TraCS
Professional Development Seminar, R Writing Group, Mentor Training, and training in requirements...

## Key facts

- **NIH application ID:** 10294412
- **Project number:** 3UL1TR002489-04S1
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** John Bernard Buse
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $169,963
- **Award type:** 3
- **Project period:** 2021-06-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10294412

## Citation

> US National Institutes of Health, RePORTER application 10294412, CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults (3UL1TR002489-04S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10294412. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*